Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Kinase inhibitor (STAMP [Specifically Targeting the ABL Myristoyl Pocket] inhibitor)
How the Drug is Given:

By mouth


Indications and Usage

Asciminib is indicated for the treatment of adult patients with: 

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). 
    This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 
  • Ph+ CML in CP with the T315I mutation. 

Side effects needing medical attention

Most common adverse reactions are upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.